CorMedix Inc.CRMDNASDAQ
LOADING
|||
R&D Expense Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
108.69%
↑ 602% above average
Average (39q)
15.47%
Historical baseline
Range
High:166.13%
Low:-152.45%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 108.69% |
| Q2 2025 | -23.48% |
| Q1 2025 | 84.88% |
| Q4 2024 | 137.47% |
| Q3 2024 | 11.69% |
| Q2 2024 | -22.26% |
| Q1 2024 | -63.41% |
| Q4 2023 | -14.08% |
| Q3 2023 | -44.44% |
| Q2 2023 | 40.71% |
| Q1 2023 | 19.85% |
| Q4 2022 | 21.54% |
| Q3 2022 | -27.11% |
| Q2 2022 | 40.30% |
| Q1 2022 | -29.29% |
| Q4 2021 | -31.76% |
| Q3 2021 | 88.13% |
| Q2 2021 | -4.40% |
| Q1 2021 | 14.90% |
| Q4 2020 | -21.57% |
| Q3 2020 | -48.55% |
| Q2 2020 | 129.98% |
| Q1 2020 | -7.65% |
| Q4 2019 | 6.19% |
| Q3 2019 | -15.40% |
| Q2 2019 | 3.65% |
| Q1 2019 | 166.13% |
| Q4 2018 | -152.45% |
| Q3 2018 | 25.59% |
| Q2 2018 | -20.29% |
| Q1 2018 | -2.10% |
| Q4 2017 | 40.63% |
| Q3 2017 | 18.17% |
| Q2 2017 | 3.36% |
| Q1 2017 | 22.12% |
| Q4 2016 | -41.05% |
| Q3 2016 | 146.68% |
| Q2 2016 | 32.70% |
| Q1 2016 | 40.69% |
| Q4 2015 | -15.82% |